Lidocaine with cetylpyridinium chloride oromucosal
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oromucosal formulation of lidocaine with cetylpyridinium chloride.
Abrasions and ulcers of mouth
Teething pain - relief of
The dosage is based on Pharmacy products.
The treatment should be stopped once symptoms have resolved and should not be used for more that 7 days.
No dosage recommendation for this age group.
Children over 5 months
Apply a pea size amount of gel to the affected area of gum. This may be repeated after 3 hours, up to a maximum of 6 doses in 24 hours.
If the child vomits, spits or ingests, do not repeat the dose immediately but after 3 hours if necessary.
Children under 5 months
Precautions and Warnings
Hereditary fructose intolerance
Not all available brands are indicated for all uses
Presentations with sorbitol unsuitable in hereditary fructose intolerance
Treatment should not exceed 7 days in infants
Pregnancy and Lactation
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Last Full Review Date: September 2018
Summary of Product Characteristics: Bonjela Junior Gel. Reckitt Benckiser Healthcare (UK) Ltd. Revised July 2018.
Summary of Product Characteristics: Calgel Teething Gel. McNeil Products Limited. Revised August 2018.
Summary of Product Characteristics: Dentinox Teething Gel. DDD Limited. Revised August 2018.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.